Tenax Therapeutics, Inc. (TENX)

NCM – Real Time Price. Currency in USD

1.61

-0.01 (-0.62%)

Market open: Aug 12, 2026, 1:05 PM EDT

1.62

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

11.08.2026

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.

10.08.2026

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics Inc. (NASDAQ:TENX) stock is trading lower on Monday after the company reported topline results from its Phase 3 LEVEL study evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

10.08.2026

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

10.08.2026

Tenax Therapeutics' heart drug misses main goal in study, shares plunge

Tenax Therapeutics said on ‌Monday its experimental heart drug failed to meet the main goal of a late-stage study.

10.08.2026

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
TENX	Chardan Capital Markets	Neutral	undefined >> $5	August 11th 2026
TENX	Evercore ISI	In-line	undefined >> $5	August 11th 2026
TENX	Canaccord Genuity	Buy	undefined >> $35	July 28th 2026

Press releases

10.08.2026

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo

Tenax Therapeutics, Inc. (TENX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tenax Therapeutics, Inc. (TENX)

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

Tenax Therapeutics' heart drug misses main goal in study, shares plunge

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Videos

No Data

Upgrades / Downgrades

Press releases

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

Tenax Therapeutics' heart drug misses main goal in study, shares plunge

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Videos

No Data

Upgrades / Downgrades

Press releases

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Search stocks

Tenax Therapeutics, Inc. (TENX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tenax Therapeutics, Inc. (TENX)

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

Tenax Therapeutics' heart drug misses main goal in study, shares plunge

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Videos

No Data

Upgrades / Downgrades

Press releases

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

Tenax Therapeutics' heart drug misses main goal in study, shares plunge

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Videos

No Data

Upgrades / Downgrades

Press releases

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF